“Global Norovirus Vaccines in pipeline forecast set to grow to $158m by 2025” says new Visiongain report

19 December 2019
Pharma

Visiongain has launched a new pharma report Global Norovirus Vaccines in Pipeline Forecast 2020-2030: Takeda, Vaxart, Cocrystal Pharma, PanTheryx, Calici Therapeutics.

Norovirus has become the leading cause of medically attended acute gastroenteritis and is a common cause of outbreaks worldwide. There is no licensed norovirus vaccine yet, but there are promising candidate vaccines in the pipeline. This burden affects children under 5 years of age and people in developing countries overwhelmingly.

The lead analyst of the report commented "Despite external stimuli, such as a major donor, developed global markets are likely to provide the initial economic support for the production of norovirus vaccines for private industry. Early phase trials among adults in high-income settings have been conducted to date, leaving a need for a paediatric development plan."

Leading companies featured in the report include Takeda, Vaxart, Cocrystal Pharma, PanTheryx, Calici Therapeutics and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever